Evaluation of the API-VIGIE Monitoring System: Program to Reduce Emergency Visits for Severe Paroxysmal Alcoholism

Emergencies Clinical Trial

— EVAL-APIVIGIE  

Official title:

Evaluation of API-VIGIE Monitoring System: Program to Reduce Emergency Visits for Severe Paroxysmal Alcoholism

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05173116
• Other study ID #: 2020-08
• Status: Withdrawn
• Start date: February 2022
• Est. completion date: August 2023

Study information

• Verified date: January 2023
• Source: Centre Hospitalier Arras
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study was designed to evaluate the APIVIGIE program use at CH d'Arras. The objective of this program is to reduce repeated visits by the same patient to the emergency room for Alcoholism Severe Paroxysmal

Description:

In France, between 10% and 30% of emergency room admissions are linked to problematic alcohol consumption. This considerable weight of alcohol-related problems in the current problematic of emergencies is largely unknown and can lead to blockages in emergencies.

For acute intoxication requiring emergency care, 80% of admissions concern people dependent on alcohol. Here again, this crucial clinical notion is largely ignored: when a patient in a state of intoxication arrives in the emergency room, this should not be considered as a banal and one-off event, it is necessary to put in place a care, if necessary, of addiction.

Supported by a call for projects from the Hauts-de-France Regional Health Agency, the Addictions Service of the Arras Hospital is setting up a monitoring system called APIVIGIE.

APIVIGIE program is offered to patients who present to the emergency room for a diagnosis of API after an evaluation by the liaison team of the addiction service. If the patient agrees to be part of the program, he will receive a resource card with the APIVIGIE phone number to contact if necessary.

The link will be maintained with the Addictology Care, Support and Prevention Center (CSAPA) for a period of 6 months, by telephone consultations, or by video-consultations or face-to-face consultations.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient 18 years or older;

• Participant at API-VIGIE program.

Exclusion Criteria:

• Patient's opposition to participating in the research;

• Persons under legal protection (under tutorship or curatorship);

• Person deprived of liberty;

• Pregnant or breastfeeding women.

Related Conditions & MeSH terms

• Alcoholic Intoxication
• Alcoholism
• Emergencies

Intervention

Other:
• Medical Outcomes Study Short Form 36 (SF 36)
completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
• observationnal study
data collection

Locations

Country	Name	City	State
France	Dominique LEJEUNE	Arras

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Arras	F2RSM Psy (Hauts-de-France Regional Federation for Research in Psychiatry and Mental Health)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of visits to the Emergency Reception Service for Significant Paroxysmal Alcoholics	1 year before implementation of the program and up to 1 year after implementation of the program	during 2 years
Secondary	weekly consumption of alcoholic beverages		Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)
Secondary	weekly consumption of other substances (cannabis, other substances)		Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)
Secondary	Quality of life score, measured by the Medical Outcomes Study Short Form 36 (SF-36) health scale score.	SF 36 giving a score from 0 to 100. More higher score, more better quality of life.	Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)